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Falls in ED patients: do elderly patients on
direct oral anticoagulants bleed less than
those on vitamin K antagonists?
Martin Müller1*† , Ioannis Chanias1†, Michael Nagler2, Aristomenis K. Exadaktylos1 and Thomas C. Sauter1
Abstract
Background: Falls from standing are common in the elderly and are associated with a significant risk of bleeding.
We have compared the proportional incidence of bleeding complications in patients on either direct oral
anticoagulants (DOAC) or vitamin K antagonists (VKA).
Methods: Our retrospective cohort study compared elderly patients (≥65 years) on DOAC or VKA oral anticoagulation
who presented at the study site – a Swiss university emergency department (ED) – between 01.06.2012 and 01.07.2017
after a fall. The outcomes were the proportional incidence of any bleeding complication and its components (e.g.
intracranial haemorrhage), as well as procedural and clinical parameters (length of hospital stay, admission to intensive
care unit, in-hospital-mortality). Uni- and multivariable analyses were used to compare the studied outcomes.
Results: In total, 1447 anticoagulated patients were included – on either VKA (n = 1021) or DOAC (n = 426). There were
relatively more bleeding complications in the VKA group (n = 237, 23.2%) than in the DOAC group (n = 69, 16.2%, p =
0.003). The difference persisted in multivariable analysis with 0.7-fold (95% CI: 0.5–0.9, p = 0.014) lower odds for patients
under DOAC than under VKA for presenting with any bleeding complications, and 0.6-fold (95% 0.4–0.9, p = 0.013)
lower odds for presenting with intracranial haemorrhage. There were no significant differences in the other studied
outcomes.
Conclusions: Among elderly, anticoagulated patients who had fallen from standing, those under DOACs had a lower
proportional incidence of bleeding complications in general and an even lower incidence of intracranial haemorrhage
than in patients under VKAs.
Keywords: Anticoagulants, Bleeding, Direct oral anticoagulants, Fall, Intra cranial bleeding, Syncope, Vitamin K
antagonist
Introduction
Falls are a leading cause of trauma in elderly patients pre-
senting at the emergency department (ED) [1, 2]. One of
the main type of falls are from standing and these falls are
often associated with head and neck trauma [3]. About
30% of people age 65 years and older fall at least once a
year [4]. Falls are responsible for loss of independence,
disability, and even death in the elderly [5–7]. In addition
to individual harm, falls pose an important economic bur-
den to any healthcare system, with costs ranging between
0.9 and 1.5% of the total health care expenditure in the
USA, United Kingdom, Australia, and Europe [8]. The se-
verity of injuries after a fall increases with age [7]. The in-
creased morbidity and mortality in older patients after a
fall are partially associated with anticoagulant therapy and
the resulting increased risk of bleeding complications [9].
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Anticoagulant therapy is more prevalent in elderly patients,
especially in patients with atrial fibrillation [10], and is
intended to prevent stroke [11, 12]. Not surprisingly, it has
been shown that both falls and oral anticoagulation are risk
factors for the development of intracranial haemorrhage
[13, 14]. Thus, in up to 50% of the patients with an indica-
tion for anticoagulation for stroke prevention, anticoagula-
tion is not prescribed, as the perceived greater risk of
bleeding – especially after falls – outweighs the perceived
risk of stroke [15, 16] and a prior history of a fall is a clinic-
ally useful risk factor for poor outcome in anticoagulated
elderly patients [17]. This underlines the need for trials on
the interaction between falls and anticoagulation.
In recent years, DOACs have gradually replaced clas-
sical vitamin K antagonists (VKA) in anticoagulation
therapy, even in special patient groups such as elderly
patients [18]. In this context, it is important to examine
the risk of bleeding complications in patients under dif-
ferent treatments for anticoagulation.
A meta-analysis of randomised controlled trials in elderly
patients found no increased risk for major bleeding in pa-
tients on DOAC compared to patients on VKA [19]. A
subgroup analysis from the ENGAGE AF trial found fewer
bleeding complications and a reduction in short-term mor-
tality in patients on edoxaban compared to patients on
warfarin [20]. Although the data suggest that DOACs are
an effective and safe alternative to VKA in elderly patients,
these results must be confirmed with real-life data for all
DOACs, as elderly patients in clinical trials are known to
have fewer comorbidities and better adherence to medica-
tion than real-life patients, where non-adherence to medi-
cation therapy is often reported [21, 22].
Therefore, we aim to analyse our series of elderly, antic-
oagulated ED patients admitted after a fall and compare
patients on DOAC with those on VKA with regards to
bleeding complications. The primary outcome of this in-
vestigation is the proportional incidence of any bleeding
complications in DOAC vs. VKA patients after falls from
standing. Secondary outcomes are the proportional inci-
dence of different types of haemorrhage (e.g. intracranial),
admission to the intensive care (ICU), length of ED and
hospital stay as well as in-hospital mortality.
Methods
Study design and setting
This retrospective cohort study was conducted at the
interdisciplinary adult ED of Bern University Hospital,
Inselspital, Switzerland. In this Level 1 trauma centre,
about 45,000 patients from a catchment area of 2 million
people are seen each year [23].
Inclusion criteria
We included patients of at least 65 years of age on oral
anticoagulants, i.e. DOAC or VKA therapy, admitted
after a fall from standing for whatever reason (including
syncope, trips and slipping and falls from fewer than
three stairs) over the study period (01.06.2012 to
01.07.2017).
Exclusion criteria
The exclusion criteria were i) age < 65 years, ii) no docu-
mented oral anticoagulation on ED admission, iii) no
acute fall from standing as the reason for ED admission.
Study outcomes
The primary study outcome was the proportional incidence
in any documented bleeding complications - including intra-
cranial haemorrhage (i.e. epidural haematoma, subdural
haematoma, intracerebral bleeding, subarachnoid bleeding),
abdominal bleeding, thoracic bleeding, arterial soft tissue
haematoma, epistaxis, venous soft tissue haematoma. “Any
type of bleeding” was chosen as composite outcome because
any bleeding resulted in an emergency department presenta-
tion and were therefore judged to be clinically relevant.
Secondary outcomes were i) proportional incidence of
specific types of bleeding, particularly intracranial haem-
orrhage, ii) procedural outcomes (length of hospital stay
and in-hospital as well as ICU admission), and iii) clin-
ical outcomes (in-hospital mortality).
Data handling
The medical report included the patient’s history, a com-
prehensive list of diagnoses, medication intake, clinical
findings, and discharge procedure and was routinely
stored electronically in full text in our computerised
database (E-Care, ED 2.1.3.0, Turnhout, Belgium).
For data extraction, we conducted a broad keyword
search in the whole patient database during the study
period, including all substance and brand names of oral
anticoagulant drugs approved in Switzerland, together with
variants in spelling and common mistakes (DOAC: apixa-
ban, dabigatran, edoxaban, rivaroxaban, VKA: acenocou-
marol, phenprocoumon and warfarin), combined with the
logic operator “OR” (n = 14,684). In the resulting dataset, a
sensitive keyword search was used to identify patients with
falls, tripping, slipping, and syncope (Flowchart: Fig. 1). The
medical reports of the identified patients were analysed in
full text to exclude patients without a fall (including syn-
cope) from standing or fewer than 3 stairs.
Data extraction
Baseline characteristics were recorded, including age, sex,
type and indication for anticoagulation (atrial fibrillation,
mechanic valve, thromboembolic disease, thrombophilia,
peripheral artery disease, and postsurgical status). Data on
the fall characteristics and trauma details (ground level,
number of steps fallen, syncope), bleeding complications
and characteristics were also extracted from the medical
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record. We classified the mechanisms of the fall from
standing height into three categories:
 Category one: falls from tripping or slipping from
the patient’s own height (ground level);
 Category two: falls from fewer than three stairs.
 Category three: falls due to a syncope that do not
have the same trauma mechanism
In addition, we manually extracted specific comorbidi-
ties of the patient (diabetes, liver disease, chronic ob-
structive lung disease (COPD), malignancy, congestive
heart failure, past myocardial infarction, peripheral arter-
ial disease (PAVD), past cerebrovascular insult / transi-
ent ischaemic attack, hemiplegia, dementia, renal
insufficiency, connective tissue disease, alcoholism, pep-
tic ulcer disease) and risk factors for falls and bleeding
(previous falls, HAS-BLED-score) from the medical re-
port. In addition, the group of patients were charac-
terised by extracting laboratory values (i.e. haemoglobin,
platelets, leucocytes, INR, creatinine, sodium, and potas-
sium) from the computerised database. Therapy to in-
hibit platelet aggregation was also recorded.
Handling of missing data
Clinical characteristics were coded as present if they were
documented in the comprehensive medical report of the
ED. No documentation of clinical characteristic was coded
as not present. All covariables that were included in the
multivariable models had no missing data. For the docu-
mentation of the indication of OAC, a “non-docu-
mented”-category was coded. For further characteristics,
such as laboratory data (Supplement 1), the numbers (per
cent) of non-missing values are shown.
Data analysis
The analysis was performed with Stata® 13.1 (StataCorp,
The College Station, Texas, USA). For descriptive ana-
lysis, categorical variables were presented as absolute
numbers, accompanied by relative numbers. Continuous
variables were presented as medians with interquartile
ranges. The distributions in the two different study
groups (DOAC vs. VKA) were compared using the chi
square test (for categorical variables) or the Wilcoxon
rank sum test (for continuous variables).
Multivariable regression analysis was performed to
quantify the impact of the type of anticoagulation on the
presentation with bleeding complications (primary or
secondary outcomes) after a fall from standing. All effect
sizes were presented as odds ratios (OR) or geometric
mean ratios (GMR) with 95% confidence interval.
Multivariable logistic regression analysis was per-
formed that included all variables from the HAS-BLED
score and Charlson Comorbidity Index [24] that had
Fig. 1 Flowchart of the study. Abbreviations: DOAC, direct oral anticoagulant; VKA, Vitamin K antagonist
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shown at least slight evidence for an association with the
type of anticoagulation (p < 0.2). Additionally, age, the
number of medications, and number of diagnoses were
incorporated into the final model.
Sensitivity analysis was based on i) a stepwise back-
ward selection (p < 0.2) logistic regression model and ii)
a multivariable model with adjustment for the Charlson
Comorbidity Index and the HAS-BLED score. The effect
of the type of anticoagulation on secondary outcomes
was studied with a backward selection logistic regression
model (for binary outcomes) or a linear regression
model adjusted for the variables identified through uni-
variable analysis (for continuous outcomes). In linear re-
gression models, the outcome was ln-transformed and
the coefficients expressed as exponentials, corresponding
to the GMR [25].
p < 0.05 was set as significant. No adjustment for mul-
tiple testing was performed. There was no formal study
size calculation as all ED consultations from the start of
the use of the digital, comprehensive documentation in
E-Care, ED 2.1.3.0, Turnhout, Belgium were included.
Ethics
The present investigation was registered and approved by
the Ethics Committee of Canton Bern, Switzerland under
the number 073/2015. According to Swiss law, no informed
consent is needed for the use of coded patient data.
Results
Over the study period, 1447 anticoagulated patients aged
at least 65 years presented to our ED after an acute fall
from standing. Of these patients, 1021 (70.6%) were on
VKA and 426 (29.4%) on DOAC therapy (Fig. 1).
Patient characteristics
The median age was 80 (IQR 74–85) years and 50.1% of
the patients were males. There was no significant differ-
ence between the treatment groups with respect to ei-
ther age (p = 0.240) or gender (p = 0.681).
There were relatively more patients with previous
cerebrovascular insult or transient ischemic attack (p =
0.001), malignancy (p = 0.045), dementia (p < 0.001), al-
coholism (p < 0.001), peptic ulcer disease (p = 0.025) as
well as an increased number of medications taken (p =
0.008) in the group of patients under DOAC. The, per-
centage of patients with peripheral artery disease was
higher in the VKA group (Table 1).
As regards the indications for oral anticoagulation, there
were more patients with atrial fibrillation and past surgical
status in the DOAC group but more patients with artificial
valves in the VKA group (Table 2). Furthermore, the indi-
cation was not documented in ≥10% in both groups, with
a higher percentage in the VKA group.
The intake of antiplatelet agents and specific labora-
tory values are shown in Supplement 1. No significant
differences were found between the two anticoagulation
groups with respect to long term therapy with antiplate-
let agents (p = 0.067) and the use of non-steroidal anti-
rheumatic medication (p = 0.124). As regards the
laboratory values, there was a slightly higher creatinine
value in the VKA patient group (p = 0.006). An elevated
international normalised ratio (INR) in the VKA group
was as expected, because of the mechanism of action of
this medication.
Trauma details
In total, 81.3% of the patients suffered falls from ground
level, 3.7% falls from stairs, and 15% were admitted after
a syncope. There was no significant difference between
the type of anticoagulation and the mechanism of
trauma (p = 0.834).
Type of bleeding and frequency in each group
There were relatively more bleeding complications in
the VKA group (n = 237, 23.2%) than in the DOAC
group (n = 69, 16.2%, p = 0.003).
The proportional incidence of intracranial haemor-
rhage was also slightly higher in the VKA group (15.7%
versus 9.9%, p = 0.004).
The distribution of bleeding complications in the differ-
ent study groups is shown in Table 3. The most frequent
type of intracranial haemorrhage was subdural haemor-
rhage (VKA 48.5% vs. DOAC 36.2%). After intracranial
haemorrhage, venous soft tissue haematoma was the most
common bleeding type (VKA 15.6% vs. DOAC 13.0%).
The impact of type of anticoagulation on the
proportional incidence of any bleeding and the
secondary outcomes
The univariable analysis for the composite primary out-
come “any bleeding” and the secondary outcomes is
shown in Table 4.
Significant reductions (p = 0.003 and p = 0.004) of the
odds for bleeding in DOAC compared to VKA patients
were found for any bleeding complication and intracra-
nial haemorrhage in the univariable analysis.
The multivariable analyses were performed to determine
the impact of the type of anticoagulation on the presenta-
tion with bleeding complications after a fall from standing
– including characteristics presented in Tables 1 and 2
(with p < 0.2). The bleeding odds ratio (DOAC vs. VKA)
was 0.678 (95% CI: 0.5–0.9) see Table 5).
Sensitivity analysis
A sensitivity analysis for the primary outcome of any
bleeding including i) a stepwise backward selection (p <
0.2) logistic regression model or ii) an adjustment for
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Table 1 Baseline characteristics for each type of anticoagulation
VKA (n = 1021) DOAC (n = 426) Total (n = 1447) p
Demographic characteristic
Sex, male, [n (%)] 508 (49.8) 217 (50.9) 725 (50.1) 0.681
Age (years), med (IQR) 80 (74–85) 80 (74–85) 80 (74–85) 0.240
Comorbidities
HAS-BLED Score, [med (iqr)] 3 (2–3) 3 (2–3) 3 (2–3) 0.083
Charlson Comorbidity Index, [med (iqr)] 6 (4–8) 6 (5–8) 6 (4–8) 0.015
No. of drugs, [med (iqr)] 7 (4–10) 8 (5–10) 7 (5–10) 0.008
No. of diagnoses, [med (iqr)] 5 (4–6) 5 (4–6) 5 (4–6) 0.004
Hypertension, [n (%)] 744 (72.9) 325 (76.3) 1069 (73.9) 0.177
Diabetes, [n (%)] 229 (22.4) 99 (23.2) 328 (22.7) 0.737
CHF, [n (%)] 225 (22.0) 103 (24.2) 328 (22.7) 0.375
Coronary artery disease, [n (%)] 97 (9.5) 43 (10.1) 140 (9.7) 0.728
Cerebrovascular disease,[n (%)] 228 (22.3) 131 (30.8) 359 (24.8) 0.001
Hemiplegia, [n (%)] 115 (11.3) 50 (11.7) 165 (11.4) 0.796
Renal insufficiency, [n (%)] 401 (39.3) 145 (34.0) 546 (37.7) 0.061
PAVD, [n (%)] 117 (11.5) 27 (6.3) 144 (10.0) 0.003
Liver disease, [n (%)] 17 (1.7) 13 (3.1) 30 (2.1) 0.092
COPD, [n (%)] 98 (9.6) 53 (12.4) 151 (10.4) 0.107
Malignancy, [n (%)] 104 (10.2) 59 (13.8) 163 (11.3) 0.045
Dementia, [n (%)] 106 (10.4) 73 (17.1) 179 (12.4) < 0.001
Alcoholism, [n (%)] 8 (0.8) 14 (3.3) 22 (1.5) < 0.001
Connective tissue disease, [n (%)] 36 (3.5) 14 (3.3) 50 (3.5) 0.820
Peptic ulcer disease, [n (%)] 174 (17.0) 94 (22.1) 268 (18.5) 0.025
AIDS, [n (%)] 0 (0.0) 0 (0.0) 0 (0.0) –
History of bleeding, [n (%)] 177 (17.3) 78 (18.3) 255 (17.6) 0.658
Abbreviations: CHF Congestive heart failure, COPD Chronic obstructive pulmonary disease, CVI Cerebrovascular insult, DOAC Direct oral anticoagulant, iqr
Interquartile range, med Median, TIA Transient ischemic attack, PAVD Peripheral artery disease, VKA Vitamin K antagonist
Table 2 Information on anticoagulation in the study groups
VKA (n = 1021) DOAC (n = 426) Total (n = 1447) p
Type OAC, [n (%)]
VKA 1021 (100.0) 0 (0.0) 1021 (70.6)
DOAC
Rivaroxaban – 362 (85.0) 362 (25.0)
Apixaban – 44 (10.3) 44 (3.0)
Edoxaban – 5 (1.2) 5 (0.3)
Dabigatran – 15 (3.5) 15 (1.0) < 0.001
Indication OAC, [n (%)]
Atrial fibrillation 546 (53.5) 294 (69.0) 840 (58.1)
Mechanical heart valve 34 (3.3) 3 (0.7) 37 (2.6)
Thromboembolic event 175 (17.1) 77 (18.1) 252 (17.4)
Post-surgery 0 (0.0) 6 (1.4) 6 (0.4)
Other 20 (2.0) 4 (0.9) 24 (1.7)
Not documented 246 (24.1) 42 (9.9) 288 (19.9) < 0.001
Abbreviation: DOAC Direct oral anticoagulants, OAC Oral anticoagulant, VKA Vitamin K antagonist
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the Charlson Comorbidity Index and the HAS-BLED
score and iii) restricting the analysis to the n = 1177 pa-
tient with falls from their own height (excluding syncope
and falls from stairs) revealed similar ORs of i) 0.7, 95%
CI: 0.5–0.9, p = 0.016, ii) 0.7, 95% CI: 0.5–0.9, p = 0.005,
iii) 0.7, 95% CI: 0.5–1.0, p = 0.039.
The impact of type of anticoagulation on secondary
outcomes
Taking the VKA group as baseline, we compared the sec-
ondary outcomes of intracranial haemorrhage, ICU admis-
sion, length of stay and in-hospital mortality. Apart from a
higher proportional incidence of intracranial haemorrhage
in the VKA group (OR: 0.63, 95% CI: 0.43–0.91, p = 0.013),
no significant differences (p > 0.05, see Table 6) were found
for other types of bleeding. No significant differences were
found in the length of hospital stay (p = 0.890), ICU admis-
sion (p = 0.767) or in-hospital mortality (p = 0.751).
Discussion
The study compared the proportional incidence of bleed-
ing and other clinical and procedural outcomes in elderly
patients on anticoagulation therapy with either VKA or
DOAC, after ED presentation due to falls from standing.
In the group taking DOAC, there was a lower propor-
tional incidence of all bleeding types, especially intracra-
nial haemorrhage. This is in line with other studies, that
have shown no inferiority and even lower incidences of
major life threatening bleeding in patients on long-term
DOAC therapy than with VKA [12, 26–30]. A prospect-
ive, multicentre study in the Unites States compared the
outcome after trauma of patients on different anticoagu-
lation and anti-platelet regimens. Patients on DOAC had
a significantly lower rate of intracranial haemorrhage
than with VKA, but no difference in short-term mortal-
ity [31]. Even though the median age in most studies
was above 65 years, to the best of our knowledge, no
study has compared the incidence of overall bleeding
and other clinical or procedural outcomes after falls
from standing specifically in elderly patients. This is par-
ticularly important, as this group not only exhibits a
higher incidence of atrial fibrillation or post thrombo-
embolic disease than younger patients – both indications
for long-term oral anticoagulation –, but also between
falls and other comorbidities, such as chronic renal or
liver insufficiency, peptic ulcers or multifactorial frailty.
These factors can make a decision to begin with antic-
oagulation therapy very challenging [32]. Thus, many of
these patients remain untreated, despite the indication
Table 3 Type of bleeding according to type of anticoagulation in the 306 patients with documented bleeding [n (%)]
VKA (n = 237) DOAC (n = 69) Total (n = 306)
Intracranial haemorrhage 160 (67.5) 42 (60.8) 202 (66.0)
Epidural haemorrhage 4 (1.7) 1 (1.4) 5 (1.6)
Subdural haemorrhage 115 (48.5) 25 (36.2) 140 (45.8)
Intracerebral 19 (8.0) 7 (10.1) 26 (8.5)
Subarachnoid 17 (7.2) 8 (11.6) 25 (8.2)
Subarachnoid and subdural 16 (6.8) 6 (8.7) 22 (7.2)
Subdural and intracerebral 6 (2.5) 1 (1.4) 7 (2.3)
Subarachnoid and intracerebral 5 (2.1) 1 (1.4) 6 (2.0)
Abdominal bleeding 4 (1.7) 2 (2.9) 6 (2.0)
Thoracic bleeding 5 (2.1) 1 (1.4) 6 (2.0)
Arterial soft tissue haematoma 4 (1.7) 4 (5.8) 8 (2.6)
Venous soft tissue haematoma 37 (15.6) 9 (13.0) 46 (15.0)
Epistaxis 5 (2.1) 4 (5.8) 9 (2.9)
Abbreviation: DOAC Direct oral anticoagulant, VKA Vitamin K antagonist
Table 4 The impact of type of anticoagulation on the primary
and secondary outcomes – univariable analysis
OR (95% CI)[DOAC vs. VKA] p
Any bleeding complication 0.639 (0.476–0.859) 0.003
Intracranial haemorrhage 0.589 (0.410–0.844) 0.004
Abdominal bleeding 1.199 (0.219–6.572) 0.834







Epistaxis 1.926 (0.515–7.208) 0.330
ICU admission 0.791 (0.611–1.025) 0.076
In-hospital mortality 1.186 (0.725–1.940) 0.498
GMR (95% CI)[DOAC vs.
VKA]
p
LOS hospital [days] 1.026 (0.853–1.235) 0.783
Abbreviation: DOAC Direct oral anticoagulants, GMR Geometric mean ratio, ICU
Intensive care unit, LOS Length of stay, OR Odds ratio
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for anticoagulation. They are then at increased risk of
thromboembolic events, especially ischemic stroke, ac-
companied by morbidity and mortality [15–17, 33]. If in
patients at high risk of falling one of the treatment op-
tions can be demonstrated to be associated with fewer
complications, this could not only reduce complications
in treated patients – both directly and indirectly, by re-
ducing the number of untreated patients.
We have replicated the finding of other studies that
showed no differences between the two study groups in
clinical or other procedural outcomes [34, 35]. This
stands in contrast to other studies, that have shown
lower mortality in patients under DOAC [20, 34]. Feeney
et al. showed that the prognosis of anticoagulated pa-
tients who had suffered blunt traumatic intracranial
haemorrhage after a fall depends on the type of anticoa-
gulation; patients under DOAC therapy exhibited lower
mortality and fewer interventions, irrespective of the se-
verity of the injury and comorbidities [34]. Although
there was no age restriction, the mean age in this study
cohort was 75 years. Increased mortality in anti-
coagulated patients under VKA has also been recently
reported for elderly (≥60 years of age) patients treated at
an ICU after traumatic brain injury – irrespective of the
trauma mechanism [27]. This is an interesting finding,
as reversal agents are more often administered to VKA
than to DOAC patients after trauma [27, 36].
Limitations
Our study has several limitations: Although we have made
every effort to ensure the best possible data quality, docu-
mentation errors cannot be ruled out for any retrospective
evaluation. Nevertheless, documentation error is assumed
to be equally distributed in all included groups and should
therefore not compromise the findings of this study. This
is particular the case for the diagnosis bias of bleeding
complications. The physician on duty decided on the diag-
nostic pathway. Such a diagnosis bias is thought to intro-
duce a non-differential misclassification, i.e. equally
distributed between DOAC and VKA patients, and should
not bias the obtained effect sizes.
Although multivariable analysis and sensitivity analyses
were used to take confounding into account, known and
unknown confounders might have been missed.
As this was a single centre evaluation at a university
hospital, our results may not be representative of other
populations.
Adherence to anticoagulation therapy could not be as-
sured in the DOAC group, as – in contrast to the VKA
group – the INR is not a marker of the anticoagulation ef-
fect, Moreover, the concentration of DOAC is not rou-
tinely determined. This could be of particular importance,
as diseases of the elderly such as renal insufficiency lead to
increased serum levels of DOAC [37], although the correl-
ation with the incidence of bleeding is not yet well under-
stood. However, this lack of a surrogate marker for
adherence is counterbalanced by one of the greatest
strengths of this study, its real-life design.
Additionally, there might be a selection bias, as both fatal
bleeding as well as minor bleeding that did not need ED
Table 5 The impact of type of anticoagulation on the
presentation with bleeding complications after a fall from
standing – multivariable analysis
Outcome: any bleeding OR (95% CI) p
Type of anticoagulation
VKA 1.000 base
DOAC 0.678 (0.498–0.924) 0.014
Age, per year increase 1.022 (1.003–1.041) 0.022
Hypertension 0.748 (0.553–0.012) 0.060
Cerebrovascular disease 0.570 (0.407–0.799) 0.001
Renal insufficiency 0.664 (0.489–0.901) 0.009
PAVD 0.775 (0.463–1.297) 0.332
Liver insufficiency 0.539 (0.158–1.840) 0.324
COPD 0.466 (0.263–0.826) 0.009
Malignancy 0.864 (0.551–1.356) 0.525
Dementia 0.890 (0.581–1.365) 0.594
Alcoholism 1.606 (0.598–4.311) 0.347
Peptic ulcer disease 1.257 (0.888–1.779) 0.197
No. of medications, per additional
drug more
1.016 (0.973–1.062) 0.470
No. of diagnosis, per additional
diagnosis
0.889 (0.803–0.984) 0.023
Abbreviation: COPD Chronic obstructive pulmonary disease; DOAC Direct oral
anticoagulants, No Number OR Odds ratio, PAVD Peripheral artery disease, VKA
Vitamin K antagonist
Table 6 The impact of type of anticoagulation (DOAC vs. VKA
with VKA as baseline) on secondary outcomes – multivariable
logistic backward selection analysis with variables shown in
Table 3
Outcome OR (95% CI) p
Intracranial haemorrhage 0.625 (0.432–0.906) 0.013
Abdominal bleeding 1.338 (0.24–7.471) 0.740
Thoracic bleeding 0.599 (0.069–5.174) 0.641
Arterial soft tissue haematoma 2.316 (0.575–9.334) 0.238
Venous soft tissue haematoma 0.549 (0.257–1.172) 0.121
Epistaxis 2.316 (0.575–9.334) 0.238
ICU admission 0.958 (0.719–1.276) 0.767
In-hospital mortality 1.085 (0.656–1.796) 0.751
Outcome GMR (95% CI) p
LOS hospital [days] 0.987 (0.822–1.186) 0.890
Abbreviation: DOAC Direct oral anticoagulants, GMR Geometric mean ratio, ICU
Intensive care unit, LOS Length of stay, OR Odds ratio
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presentation might not have been included in the analysis.
While some might argue that minor bleeding is not of great
interest, patients with fatal bleeding that might have oc-
curred on site after the fall might not have been admitted
to the ED, and then excluded from the analysis. However,
the expected number of immediate deaths caused by haem-
orrhage after falls from standing is low [38] and, in 95% of
all emergency calls, the emergency medical service in Bern
arrives at the site of an accident within 15min [39].
The total number of person-years under anticoagula-
tion is not known, so that only the proportional inci-
dence could be studied. Conclusions therefore can only
be drawn with caution.
Longitudinal, prospective, population-based cohort
studies are needed to allow the conclusion that – in frail
elderly patients who are at risk of future falls and with
an indication for anticoagulation – DOACs should be
favoured over VKAs in order to reduce the incidence of
bleeding complications.
Conclusion
Elderly, anticoagulated patients treated with DOAC at
the ED after a fall from standing have a reduced propor-
tional incidence of overall bleedings and intracranial
haemorrhage than elderly patients on VKA.
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